Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Resistance to immune-checkpoint blockade often occurs in treated patients. Here, the authors demonstrate that B2M loss is a mechanism of primary and acquired resistance to therapies targeting CTLA4 or PD-1 in melanoma patients.
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/4b7fd694a84645dbafce545e168de8d2 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:4b7fd694a84645dbafce545e168de8d2 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:4b7fd694a84645dbafce545e168de8d22021-12-02T17:06:10ZResistance to checkpoint blockade therapy through inactivation of antigen presentation10.1038/s41467-017-01062-w2041-1723https://doaj.org/article/4b7fd694a84645dbafce545e168de8d22017-10-01T00:00:00Zhttps://doi.org/10.1038/s41467-017-01062-whttps://doaj.org/toc/2041-1723Resistance to immune-checkpoint blockade often occurs in treated patients. Here, the authors demonstrate that B2M loss is a mechanism of primary and acquired resistance to therapies targeting CTLA4 or PD-1 in melanoma patients.Moshe Sade-FeldmanYunxin J. JiaoJonathan H. ChenMichael S. RooneyMichal Barzily-RokniJean-Pierre ElianeStacey L. BjorgaardMarc R. HammondHans VitzthumShauna M. BlackmonDennie T. FrederickMehlika Hazar-RethinamBrandon A. NadresEmily E. Van SeventerSachet A. ShuklaKeren YizhakJohn P. RayDaniel RosebrockDimitri LivitzViktor AdalsteinssonGad GetzLyn M. DuncanBo LiRyan B. CorcoranDonald P. LawrenceAnat Stemmer-RachamimovGenevieve M. BolandDan A. LandauKeith T. FlahertyRyan J. SullivanNir HacohenNature PortfolioarticleScienceQENNature Communications, Vol 8, Iss 1, Pp 1-11 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Science Q |
| spellingShingle |
Science Q Moshe Sade-Feldman Yunxin J. Jiao Jonathan H. Chen Michael S. Rooney Michal Barzily-Rokni Jean-Pierre Eliane Stacey L. Bjorgaard Marc R. Hammond Hans Vitzthum Shauna M. Blackmon Dennie T. Frederick Mehlika Hazar-Rethinam Brandon A. Nadres Emily E. Van Seventer Sachet A. Shukla Keren Yizhak John P. Ray Daniel Rosebrock Dimitri Livitz Viktor Adalsteinsson Gad Getz Lyn M. Duncan Bo Li Ryan B. Corcoran Donald P. Lawrence Anat Stemmer-Rachamimov Genevieve M. Boland Dan A. Landau Keith T. Flaherty Ryan J. Sullivan Nir Hacohen Resistance to checkpoint blockade therapy through inactivation of antigen presentation |
| description |
Resistance to immune-checkpoint blockade often occurs in treated patients. Here, the authors demonstrate that B2M loss is a mechanism of primary and acquired resistance to therapies targeting CTLA4 or PD-1 in melanoma patients. |
| format |
article |
| author |
Moshe Sade-Feldman Yunxin J. Jiao Jonathan H. Chen Michael S. Rooney Michal Barzily-Rokni Jean-Pierre Eliane Stacey L. Bjorgaard Marc R. Hammond Hans Vitzthum Shauna M. Blackmon Dennie T. Frederick Mehlika Hazar-Rethinam Brandon A. Nadres Emily E. Van Seventer Sachet A. Shukla Keren Yizhak John P. Ray Daniel Rosebrock Dimitri Livitz Viktor Adalsteinsson Gad Getz Lyn M. Duncan Bo Li Ryan B. Corcoran Donald P. Lawrence Anat Stemmer-Rachamimov Genevieve M. Boland Dan A. Landau Keith T. Flaherty Ryan J. Sullivan Nir Hacohen |
| author_facet |
Moshe Sade-Feldman Yunxin J. Jiao Jonathan H. Chen Michael S. Rooney Michal Barzily-Rokni Jean-Pierre Eliane Stacey L. Bjorgaard Marc R. Hammond Hans Vitzthum Shauna M. Blackmon Dennie T. Frederick Mehlika Hazar-Rethinam Brandon A. Nadres Emily E. Van Seventer Sachet A. Shukla Keren Yizhak John P. Ray Daniel Rosebrock Dimitri Livitz Viktor Adalsteinsson Gad Getz Lyn M. Duncan Bo Li Ryan B. Corcoran Donald P. Lawrence Anat Stemmer-Rachamimov Genevieve M. Boland Dan A. Landau Keith T. Flaherty Ryan J. Sullivan Nir Hacohen |
| author_sort |
Moshe Sade-Feldman |
| title |
Resistance to checkpoint blockade therapy through inactivation of antigen presentation |
| title_short |
Resistance to checkpoint blockade therapy through inactivation of antigen presentation |
| title_full |
Resistance to checkpoint blockade therapy through inactivation of antigen presentation |
| title_fullStr |
Resistance to checkpoint blockade therapy through inactivation of antigen presentation |
| title_full_unstemmed |
Resistance to checkpoint blockade therapy through inactivation of antigen presentation |
| title_sort |
resistance to checkpoint blockade therapy through inactivation of antigen presentation |
| publisher |
Nature Portfolio |
| publishDate |
2017 |
| url |
https://doaj.org/article/4b7fd694a84645dbafce545e168de8d2 |
| work_keys_str_mv |
AT moshesadefeldman resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT yunxinjjiao resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT jonathanhchen resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT michaelsrooney resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT michalbarzilyrokni resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT jeanpierreeliane resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT staceylbjorgaard resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT marcrhammond resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT hansvitzthum resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT shaunamblackmon resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT dennietfrederick resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT mehlikahazarrethinam resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT brandonanadres resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT emilyevanseventer resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT sachetashukla resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT kerenyizhak resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT johnpray resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT danielrosebrock resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT dimitrilivitz resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT viktoradalsteinsson resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT gadgetz resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT lynmduncan resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT boli resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT ryanbcorcoran resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT donaldplawrence resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT anatstemmerrachamimov resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT genevievemboland resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT danalandau resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT keithtflaherty resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT ryanjsullivan resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation AT nirhacohen resistancetocheckpointblockadetherapythroughinactivationofantigenpresentation |
| _version_ |
1718381727194284032 |